Evimatic goal is to achieve clinical decisions to be optimal.
We utilize artificial intelligence (AI) to assist clinicians and patients in shared decision-making.
We have developed TDApp, an AI-powered, clinician-controlled recommender system. TDApp is the first eHealth tool that generates decentralized, automated, personalized, participatory, and explanatory treatment recommendations in a format similar to clinical practice guidelines. We have implemented TDApp to assist clinicians in treatment decision-making for attention deficit hyperactivity disorder (ADHD) as a proof of concept before expanding its application to other diseases. The minimal viable product (MVP) for TDApp is planned to be launched in April 2024.